IL-17B Protein, Mouse, Recombinant (His)

IL-17A, the prototypic member of the IL-17 family, several experimental findings strongly support the role of the IL-17B/IL-17 receptor B (IL-17RB) pathway in tumorigenesis and resistance to anticancer therapies. IL-17B/IL-17RB expression patterns and biological activities in cancer and highlight issues that remain to be addressed to better characterize IL-17B and its receptor as potential targets for enhancing the effectiveness of the existing cancer therapies.

规格	价格/CNY		数量
100 μg	￥ 3,100	5日内发货
500 μg	￥ 12,400	5日内发货
1 mg	￥ 20,700	5日内发货

规格

价格/CNY

货期

数量

100 μg

￥ 3,100

5日内发货

500 μg

￥ 12,400

5日内发货

1 mg

￥ 20,700

5日内发货

产品描述

种属	Mouse
表达系统	E. coli
标签	N-His
蛋白编号	Q9QXT6
别名	IL20, interleukin 17B, interleukin 20, IL-17B, MGC138901, ZCYTO7, NIRF, Cytokine CX1, MGC138900
蛋白构建	His21-Phe180
蛋白纯度	> 95% as determined by Tris-Bis PAGE
分子量	19.1 kDa (predicted) same as Tris-Bis PAGE result.

内毒素	< 1 EU/μg by the LAL method.
缓冲液	Lyophilized from a solution filtered through a 0.22 μm filter, containing 20 mM PB, 2 mM DTT, 300 mM NaCl, 200 mM Arginine (pH 7.0). Typically, 8% trehalose is incorporated as a protective agent before lyophilization.
复溶方法	Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.
存储	It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
运输方式	In general, Lyophilized powders are shipping with blue ice.
研究背景	IL-17A, the prototypic member of the IL-17 family, several experimental findings strongly support the role of the IL-17B/IL-17 receptor B (IL-17RB) pathway in tumorigenesis and resistance to anticancer therapies. IL-17B/IL-17RB expression patterns and biological activities in cancer and highlight issues that remain to be addressed to better characterize IL-17B and its receptor as potential targets for enhancing the effectiveness of the existing cancer therapies.